Janet S Wiegand Selected Research

snake venom protein C activator

1/2020	DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas.
12/2019	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janet S Wiegand Research Topics

Disease

2	Neoplasms (Cancer) 01/2020 - 12/2019
2	Thrombocytopenia (Thrombopenia) 01/2020 - 12/2019
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2020
1	Drug-Related Side Effects and Adverse Reactions 12/2019
1	Leukemia 12/2019

Drug/Important Bio-Agent (IBA)

2	DT2216IBA 01/2020 - 12/2019
2	snake venom protein C activatorIBA 01/2020 - 12/2019
2	navitoclaxIBA 01/2020 - 12/2019
1	Proteolysis Targeting ChimeraIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 12/2019